Enterprise software developer Damstra Holdings confirms a non-binding bid from technology-focused private equity firm Accel-KKR. Meanwhile, Quadrant Private Equity has exited leakproof apparel company Modibodi for A$140 million ($95.4 million), and Infensa Bioscience, an Australian company that uses spider venom to treat heart attack or stroke, has raised A$23 million ($15.6 million).
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
